Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer

Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Treatment in Patients With Mammary Gland Cancer

Neoadjuvant chemotherapy is frequently proposed to patients with mammary gland cancer. The aim is to reduce tumor volume before surgical therapy. Obtaining a pathologic Complete Response (pCR) is regarded as a good prognostic factor with less risk of recurrence. The rate of pCR is about 20%, although there are important variations according to tumor subtype and the type of treatment. The objective of the new therapeutic strategies is to increase this response rate.

The purpose of this study is to investigate the possibility of early evaluation of neoadjuvant chemotherapy response after one cycle of neoadjuvant chemotherapy by positron emission tomography (PET) with (18) F-fluorodeoxyglucose (FDG) in patients.

Inclusion Criteria:

• patient having been informed of the study
• patient affiliated to a social health insurance
• ≥ 18 years
• patient presenting a breast cancer histologically confirmed
• indication of neoadjuvant chemotherapy treatment (classification UICC: II or III)
• patient agrees with exploitation of his clinical, biological and image data

Exclusion Criteria:

• distant metastasis
• contraindications to chemotherapy
• contraindications to surgery
• refusal
• serious illness not balanced, subjacent infection
• pregnancy or breast feeding
• diabetes not controlled (glycemia> 8 mmol/L)
• psychiatric disease
• patient under supervision, trusteeship or safeguard of justice